You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for New Drug Application (NDA): 022198


✉ Email this page to a colleague

« Back to Dashboard


NDA 022198 describes SANCUSO, which is a drug marketed by Cumberland and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the SANCUSO profile page.

The generic ingredient in SANCUSO is granisetron. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the granisetron profile page.
Summary for 022198
Tradename:SANCUSO
Applicant:Cumberland
Ingredient:granisetron
Patents:1
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 022198
Generic Entry Date for 022198*:
Constraining patent/regulatory exclusivity:
Dosage:
FILM, EXTENDED RELEASE;TRANSDERMAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022198
Medical Subject Heading (MeSH) Categories for 022198
Suppliers and Packaging for NDA: 022198
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SANCUSO granisetron FILM, EXTENDED RELEASE;TRANSDERMAL 022198 NDA Cumberland Pharmaceuticals Inc. 66220-637 66220-637-31 168 h in 1 POUCH (66220-637-31)
SANCUSO granisetron FILM, EXTENDED RELEASE;TRANSDERMAL 022198 NDA Cumberland Pharmaceuticals Inc. 66220-637 66220-637-72 168 h in 1 POUCH (66220-637-72)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength3.1MG/24HR
Approval Date:Sep 12, 2008TE:RLD:Yes
Patent:7,608,282Patent Expiration:Jan 22, 2025Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.